AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, driven by strong sales of Skyrizi and Rinvoq. The company remains a 'Buy' due to solid fundamentals and attractive valuation, though risks include competition and clinical trial outcomes. Upcoming industry events may cause short-term volatility, but momentum points to a price target of $292.
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
AbbVie announced that the FDA has granted Breakthrough Therapy Designations (BTDs) for its investigational drug Temab-A (telisotuzumab adizutecan) in treating colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Temab-A, a next-generation ...
AbbVie's stock performance shows that investors who bought shares during periods of market pessimism, such as after the Allergan selloff in 2019, earned higher returns than those who bought on positive drug approval news. For example, buying AbbVie a...
The Phase 3 EPCORE DLBCL-2 trial showed that adding epcoritamab, a bispecific antibody, to standard R-CHOP therapy significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with intermediate to...
